Siemens Fonds Invest GmbH Trims Position in Johnson & Johnson (NYSE:JNJ)

Siemens Fonds Invest GmbH cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 85.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,227 shares of the company's stock after selling 66,917 shares during the period. Siemens Fonds Invest GmbH's holdings in Johnson & Johnson were worth $1,624,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. MRP Capital Investments LLC lifted its holdings in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares during the last quarter. Syverson Strege & Co increased its position in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management lifted its stake in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares during the last quarter. Denali Advisors LLC grew its holdings in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after purchasing an additional 67 shares during the last quarter. Finally, Sage Mountain Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after acquiring an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $1.09 during mid-day trading on Tuesday, reaching $153.58. 6,357,723 shares of the company were exchanged, compared to its average volume of 7,961,745. The company has a fifty day simple moving average of $156.06 and a 200-day simple moving average of $153.80. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $369.52 billion, a PE ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.